Oxidative stress markers in adults with type 1 diabetes versus LADA.
Official title: Evaluation of Oxidative Stress: Comparison Between Type 1 Diabetes Mellitus and Latent Autoimmune Diabetes in Adults
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07434154 · Data updated 2026-11-12
This project will see if blood markers of oxidative stress differ between adults with type 1 diabetes and adults with LADA.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Locations | 1 site (Pavia, Pavia) |
| Status | Recruiting |
| Started | October 1, 2025 |
| Main results expected | August 31, 2026 |
| Study ends | August 31, 2026 |
| Registry record updated | April 2, 2026 |
| Trial ID | NCT07434154 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with known or newly diagnosed type 1 diabetes or LADA who can give informed consent and attend the outpatient clinic at IRCCS Policlinico San Matteo are ideal candidates.
✕Probably not a fit
People younger than 18 or older than 75, those without T1DM or LADA, or anyone unable or unwilling to provide informed consent are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational study enrolling 75 adults with type 1 diabetes and 75 adults with latent autoimmune diabetes in adults (LADA), all aged 18–75 and recruited from the outpatient diabetes center at IRCCS Policlinico San Matteo. Participants undergo a single visit for medical history and blood sample collection to measure pro-oxidant and antioxidant markers (d-ROMs, BAP, OXY-Adsorbent, -SHp, anti-ROMs) using the FREE Duo analyzer. For newly diagnosed (incident) cases a follow-up visit at 3 months will compare changes in HbA1c with changes in the oxidative biomarkers. Secondary analyses will examine associations between biomarkers and glycemic control and whether biomarkers cluster differently by diagnosis.
Why it matters
Potential benefit: If successful, this could identify oxidative stress biomarkers that help distinguish T1DM from LADA and guide more tailored monitoring or interventions.
How similar studies have gone: Oxidative stress markers have been studied broadly in diabetes, but direct head-to-head comparisons between T1DM and LADA are limited, making this a relatively novel comparison.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with with already known or newly diagnosed type 1 diabetes mellitus or LADA Patients aged ≥ 18 years and ≤ 75 years Patients of both sexes All patients will be selected among outpatients attending the Center of Diabetes and Metabolic Diseases of First Department of Internal Medicine, IRCCS Policlinico San Matteo Foundation. Exclusion Criteria: Patients refusing to sign informate consent.
Where it's running
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Differentiating heart disease in autoimmune vs. type 2 diabetes
This study tests whether adult-onset autoimmune diabetes (AID/LADA) and type 2 diabetes (T2D) differ in how diabetic heart disease develops, using advanced heart imaging in people with AID, T2D, and healthy controls.
-
VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system
This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.
-
New gene therapies VV-14299 and VV-14300 for adults with Type 1 Diabetes failing automated insulin delivery
This study tests VV-14299 and VV-14300, or VV-14300 alone, in adults with long-standing Type 1 Diabetes whose blood sugar remains poorly controlled despite using an automated insulin delivery system.
-
Oral verapamil in newly diagnosed children and teens with type 1 diabetes
This study tests whether taking verapamil by mouth can help preserve pancreatic beta cells and reduce insulin needs in kids and teens with recently diagnosed type 1 diabetes.
-
Preventing device-related skin rashes in kids with type 1 diabetes using hydrocolloid vs silicone patches
This study tests whether silicone-based or hydrocolloid patches help prevent recurring skin irritation from insulin pumps or CGMs in children and teens with type 1 diabetes.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.